Amarin Corp Plc (AMRN)

[north40000]

Reading its earnings reports, it’s apparent that BMY is experiencing the same problems that AMRN faced years ago. Sales of key drugs have fallen, notwithstanding multiple and extensive TV ads directed to patients and doctors. A few of those drugs will have generic competition on patent expiration in addition to negotiated price reduction in light of recent Congressional legislation. 2500 person layoffs are in the future for BMY. Debt accrued for a pair of acquisitions this year also is a problem in light of much higher interest rates in 2024, in contrast to AMRN that has no debt.

BTW, we deliberately purchased those 100 AMRN shares at $0.9638/share AH last evening. I had intended to purchase up to 900 more but a retirement party we attended lasted beyond last trade at 8 pm.